80 results on '"Carballido-Rodríguez, Joaquín"'
Search Results
2. Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in Spain
- Author
-
Couñago, Felipe, Martínez-Ballesteros, Claudio, Artigas, Carlos, Díaz-Gavela, Ana Aurora, Gómez, Luis Leonardo Guerrero, Lillo-García, María Eugenia, Chicharo, José Reinaldo, Recio, Manuel, Maldonado, Antonio, Thuissard, Israel J., Andreu-Vázquez, Cristina, Sanz-Rosa, David, Conde-Moreno, Antonio José, Marcos, Francisco José, García, Sofía Sánchez, Martínez-Salamanca, Juan Ignacio, Carballido-Rodríguez, Joaquin, Hornedo, Javier, and Cerro, Elia del
- Published
- 2020
- Full Text
- View/download PDF
3. Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients
- Author
-
Alcaraz, Antonio, Rodríguez-Antolín, Alfredo, Carballido-Rodríguez, Joaquín, Castro-Díaz, David, Medina-Polo, José, Fernández-Gómez, Jesús M., Ficarra, Vincenzo, Palou, Joan, Ponce de León Roca, Javier, Angulo, Javier C., Esteban-Fuertes, Manuel, Cózar-Olmo, José M., Pérez-León, Noemí, Molero-García, José M., Fernández-Pro Ledesma, Antonio, Brenes-Bermúdez, Francisco J., and Manasanch, José
- Published
- 2021
- Full Text
- View/download PDF
4. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment—the QUALIPROST study
- Author
-
Alcaraz, Antonio, Carballido-Rodríguez, Joaquín, Unda-Urzaiz, Miguel, Medina-López, Rafael, Ruiz-Cerdá, José L., Rodríguez-Rubio, Federico, García-Rojo, Darío, Brenes-Bermúdez, Francisco J., Cózar-Olmo, José M., Baena-González, Víctor, and Manasanch, José
- Published
- 2016
- Full Text
- View/download PDF
5. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of Serenoa repens versus Tamsulosin Plus 5-Alpha-Reductase Inhibitors for Moderate-to-Severe LUTS-BPH Patients: Results of a Paired Matched Clinical Study
- Author
-
Alcaraz, Antonio, Castro-Díaz, David, Gacci, Mauro, Salonia, Andrea, Ficarra, Vincenzo, Carballido-Rodríguez, Joaquín, Rodríguez-Antolín, Alfredo, Medina-Polo, José, Fernández-Gómez, Jesús M, Cózar-Olmo, José M, Búcar-Terrades, Santiago, Pérez-León, Noemí, Brenes-Bermúdez, Francisco J, Molero-García, José M, Fernández-Pro-Ledesma, Antonio, Herdman, Michael, Angulo, Javier C, Manasanch, José, and On Behalf Of The Qualiprost Study Group
- Subjects
5-alpha-reductase inhibitors ,hexanic extract of Serenoa repens ,prostate ,quality of life ,moderate-severe LUTS ,BPH ,tamsulosin ,General Medicine ,combination therapy ,urinary symptoms - Abstract
The objective of this subset analysis was to evaluate and compare the efficacy and tolerability of two combination treatments for men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). Data were from a real-world, open-label, prospective, and multicenter study performed in outpatient urology clinics. Men with moderate-to-severe LUTS/BPH received 6-month treatment with tamsulosin (TAM) in combination with either the hexanic extract of S. repens (HESr) or a 5-alpha-reductase inhibitor (5ARI). Changes in urinary symptoms and quality of life were measured using the IPSS and BII questionnaires, respectively. Treatment tolerability was assessed by recording adverse effects (AEs). Patients in the two study groups were matched using iterative and propensity score matching approaches. After iterative matching, data were available from 136 patients (n = 68 treated with TAM + 5ARI, n = 68 with TAM + HESr). After 6 months of treatment, mean (SD) IPSS total score improved by 7.7 (6.3) and 6.7 (5.0) points in the TAM + 5ARI and TAM + HESr groups, respectively (p = 0.272); mean BII total scores improved by 3.1 (2.9) and 2.9 (2.4) points (p = 0.751), respectively. AEs were reported by 26.5% and 10.3% of patients in the same groups, mostly affecting sexual function (p < 0.027). When used in a real-world setting to treat patients with moderate-severe LUTS/BPH, 6-month treatment with TAM + HESr was as effective as TAM + 5ARI, but with better tolerability.
- Published
- 2022
- Full Text
- View/download PDF
6. mpMRI-US Fusion-Guided Targeted Cryotherapy in Patients with Primary Localized Prostate Cancer: A Prospective Analysis of Oncological and Functional Outcomes
- Author
-
Fernández-Pascual, Esaú, primary, Manfredi, Celeste, additional, Martín, Cristina, additional, Martínez-Ballesteros, Claudio, additional, Balmori, Carlos, additional, Lledó-García, Enrique, additional, Quintana, Luis Miguel, additional, Curvo, Raphael, additional, Carballido-Rodríguez, Joaquín, additional, Bianco, Fernando J., additional, and Martínez-Salamanca, Juan Ignacio, additional
- Published
- 2022
- Full Text
- View/download PDF
7. Valor pronóstico de ERG, PTEN, SPINK1, Ki-67, RA y C-MYC en la predicción de recidiva bioquímica tras prostatectomía radical en el cáncer prostático
- Author
-
Cambronero Santos, Javier, Carballido Rodríguez, Joaquín, Cambronero Santos, Javier, and Carballido Rodríguez, Joaquín
- Abstract
El cáncer prostático (CAP) es de gran prevalencia en el mundo desarrollado, y produce un enorme impacto en morbimortalidad y costes de salud pública. Tras la PR con intención curativa el 25% de los pacientes sufrirán una recidiva bioquímica (RBQ), aunque solo la mitad de ellos tendrán progresión clínica. Poder estadificar a los pacientes correctamente según la extensión tumoral y el riesgo de recidiva o progresión permitiría evitar sobretratamientos con secuelas importantes, indicando más vigilancia activa y evitando tratamientos adyuvantes o de rescate innecesarios. Para ello se utilizan herramientas predictivas como los nomogramas y scores construidos con distintas variables clínico-patológicas, biomarcadores inmunohistoquímicos (IHQ), paneles multigenéticos o pruebas de imagen como la Resonancia magnética multiparamétrica (RMm). Objetivos: Valorar la capacidad pronóstica de RBQ de 7 biomarcadores estudiados mediante IHQ en una población de pacientes con CAP localizado sometidos a Prostatectomía radical (PR). Construir un score predictivo de RBQ basado en CAPRA-S junto a los biomarcadores que pueda mejorar de forma coste-efectiva a otros modelos que incorporan RMm o paneles multigenéticos comercializados (Decipher®). Validar el score en la población y comparar su C-index respecto a CAPRA-S y a otros modelos predictivos...
- Published
- 2022
8. Valor pronóstico de ERG, PTEN, SPINK1, Ki-67, RA y C-MYC en la predicción de recidiva bioquímica tras prostatectomía radical en el cáncer prostático
- Author
-
Carballido Rodríguez, Joaquín, Cambronero Santos, Javier, Carballido Rodríguez, Joaquín, and Cambronero Santos, Javier
- Abstract
El cáncer prostático (CAP) es de gran prevalencia en el mundo desarrollado, y produce un enorme impacto en morbimortalidad y costes de salud pública. Tras la PR con intención curativa el 25% de los pacientes sufrirán una recidiva bioquímica (RBQ), aunque solo la mitad de ellos tendrán progresión clínica. Poder estadificar a los pacientes correctamente según la extensión tumoral y el riesgo de recidiva o progresión permitiría evitar sobretratamientos con secuelas importantes, indicando más vigilancia activa y evitando tratamientos adyuvantes o de rescate innecesarios. Para ello se utilizan herramientas predictivas como los nomogramas y scores construidos con distintas variables clínico-patológicas, biomarcadores inmunohistoquímicos (IHQ), paneles multigenéticos o pruebas de imagen como la Resonancia magnética multiparamétrica (RMm). Objetivos: Valorar la capacidad pronóstica de RBQ de 7 biomarcadores estudiados mediante IHQ en una población de pacientes con CAP localizado sometidos a Prostatectomía radical (PR). Construir un score predictivo de RBQ basado en CAPRA-S junto a los biomarcadores que pueda mejorar de forma coste-efectiva a otros modelos que incorporan RMm o paneles multigenéticos comercializados (Decipher®). Validar el score en la población y comparar su C-index respecto a CAPRA-S y a otros modelos predictivos..., Prostate cancer (PC) is highly prevalent in the developed world, and has an enormous impact on morbidity and mortality and public health costs. After RP with curative objective, 25% of patients will suffer a biochemical recurrence (BR), although only half of them will have clinical progression. Getting the correctly staging of patients according to the tumor extension and the risk of recurrence or progression would make it possible to avoid overtreatments with significant sequelae, indicating more active surveillance and avoiding unnecessary adjuvant or salvage treatments. For this task we use predictive tools like nomograms and scores constructed with different variables, such as clinicopathological, immunohistochemical biomarkers (IHC), genetic or imaging tests such as multiparametric magnetic resonance imaging (MRI).Objectives: To assess the prognostic capacity of BR of the 7 biomarkers studied by IH in a population of patients with localized PC undergoing RP. To build a predictive score of BR based on CAPRA-S together with the biomarkers that can cost-effectively improve other models or commercial multigenetic panels. Validate the score in the population and compare C-index with respect to CAPRA-S and different predictive models...
- Published
- 2022
9. Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study
- Author
-
Alcaraz, Antonio, primary, Gacci, Mauro, additional, Ficarra, Vincenzo, additional, Medina-Polo, José, additional, Salonia, Andrea, additional, Fernández-Gómez, Jesús, additional, Ciudin, Alexandru, additional, Castro-Díaz, David, additional, Rodríguez-Antolín, Alfredo, additional, Carballido-Rodríguez, Joaquín, additional, Cózar-Olmo, José, additional, Búcar-Terrades, Santiago, additional, Pérez-León, Noemí, additional, Brenes-Bermúdez, Francisco, additional, Molero-García, José, additional, Ledesma, Antonio, additional, Herdman, Michael, additional, Manasanch, José, additional, Angulo, Javier, additional, and Group, on, additional
- Published
- 2022
- Full Text
- View/download PDF
10. Endothelial Dysfunction: An Intermediate Clinical Feature between Urolithiasis and Cardiovascular Diseases
- Author
-
Saenz-Medina, Javier, primary, Muñoz, Mercedes, additional, Rodriguez, Claudia, additional, Sanchez, Ana, additional, Contreras, Cristina, additional, Carballido-Rodríguez, Joaquín, additional, and Prieto, Dolores, additional
- Published
- 2022
- Full Text
- View/download PDF
11. Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study
- Author
-
Alcaraz, Antonio, primary, Rodríguez-Antolín, Alfredo, additional, Carballido-Rodríguez, Joaquín, additional, Castro-Díaz, David, additional, Esteban-Fuertes, Manuel, additional, Cózar-Olmo, José, additional, Ficarra, Vincenzo, additional, Medina-López, Rafael, additional, Fernández-Gómez, Jesús, additional, Angulo, Javier, additional, Medina-Polo, José, additional, Brenes-Bermúdez, Francisco, additional, Molero-García, José, additional, Fernández-Pro-Ledesma, Antonio, additional, Manasanch, José, additional, and The QUALIPROST Study Group, on behalf of, additional
- Published
- 2020
- Full Text
- View/download PDF
12. Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study
- Author
-
Pierre Fabre, Alcaraz, Antonio, Rodríguez-Antolín, Alfredo, Carballido-Rodríguez, Joaquín, Castro-Díaz, David, Esteban-Fuertes, Manuel, Cózar-Olmo, José M., Ficarra, Vincenzo, Medina López, Rafael Antonio, Fernández-Gómez, Jesús M., Angulo, Javier C., Medina-Polo, José, Brenes-Bermúdez, Francisco J., Molero, José María, Fernández-Pro-Ledesma, Antonio, Manasanch, José, Pierre Fabre, Alcaraz, Antonio, Rodríguez-Antolín, Alfredo, Carballido-Rodríguez, Joaquín, Castro-Díaz, David, Esteban-Fuertes, Manuel, Cózar-Olmo, José M., Ficarra, Vincenzo, Medina López, Rafael Antonio, Fernández-Gómez, Jesús M., Angulo, Javier C., Medina-Polo, José, Brenes-Bermúdez, Francisco J., Molero, José María, Fernández-Pro-Ledesma, Antonio, and Manasanch, José
- Abstract
To investigate whether tamsulosin (TAM) and the hexanic extract of Serenoa repens (HESr) are more effective in combination than as monotherapy in men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH). Subset analysis of data from a 6-month, multicenter observational study. Patients received either tamsulosin (0.4 mg/day) or HESr (320 mg/day) alone or in combination. Primary endpoints were change in symptoms and quality of life. Tolerability was also assessed. Seven hundred and nine patients were available for intention to treat (ITT) analysis, 263 treated with tamsulosin, 262 with HESr, and 184 with TAM + HESr. After 6 months, International Prostate Symptom Score (IPSS) scores improved by a mean (standard deviation) of 7.2 (5.0) points in the TAM + HESr group compared to 5.7 (4.3) points with TAM alone and 5.4 (4.6) points with HESr (p < 0.001). Quality of life showed greatest improvement with combination therapy (p < 0.02). Adverse effects were reported by 1.9% of patients receiving HESr, 13.3% receiving TAM, and 12.0% receiving TAM + HESr (p < 0.001). In men with moderate/severe LUTS/BPH, combination treatment with TAM + HESr produced more effective symptom relief and greater improvement in quality of life than with either treatment alone, with acceptable tolerability.
- Published
- 2020
13. Clinical drivers for imaging testing in nonmetastatic castration-resistant prostate cancer: May they be optimized?—Data of “IDENTIFICA” study.
- Author
-
Useros RodrÃguez, Eduardo, primary, Juárez, Álvaro, additional, Carballido Rodríguez, Joaquín, additional, Rubio, Jose, additional, Rodríguez Antolín, Alfredo, additional, Amores Bermúdez, Francisco Javier, additional, Medina González, Antonio, additional, Rodrigo, Miguel, additional, Moreno Jiménez, Juan, additional, Vázquez, Fernando, additional, Muñoz del Toro, Jacobo, additional, Garcia, Angela, additional, and Cózar Olmo, José Manuel, additional
- Published
- 2019
- Full Text
- View/download PDF
14. MANEJO DE LA HIPERPLASIA BENIGNA DE PRÓSTATA DURANTE LA PANDEMIA COVID-19.
- Author
-
Medina-Polo, José, Téigell Tobar, Julio, Romero-Otero, Javier, Carballido-Rodríguez, Joaquín, Domínguez-Esteban, Mario, Martínez-Berganza, María Lourdes, Miñana-López, Bernardino, Unda Urzaiz, Jesús Miguel, and Rodríguez-Antolín, Alfredo
- Published
- 2020
15. REALIDAD VIRTUAL Y NAVEGACIÓN INTRAQUIRÚRGICA EN UROLOGÍA.
- Author
-
del Pozo Jiménez, Gema, Rodríguez Monsalve, María, Carballido Rodríguez, Joaquín, and Castillón Vela, Ignacio
- Published
- 2019
16. ORQUIECTOMÍA PARCIAL EN TUMOR TESTICULAR: TÉCNICA QUIRÚRGICA Y PAPEL DE LA ECOGRAFÍA INTRAOPERATORIA.
- Author
-
del Pozo Jiménez, Gema, Castillón Vela, Ignacio, Turo Antona, Jorge, Gimeno Collado, Alfonso, and Carballido Rodríguez, Joaquín
- Published
- 2019
17. UTILIZACIÓN DE LA CAVOSCOPIA EN LA CIRUGÍA DEL CARCINOMA DE CÉLULAS RENALES CON TROMBO EN CAVA. REVISIÓN DE CONJUNTO.
- Author
-
Marcos Marín, Diego, Del Pozo Jiménez, Gema, Castillón Vela, Ignacio, and Carballido Rodríguez, Joaquín
- Published
- 2019
18. FACTORES PRONÓSTICOS DE MORTALIDAD EN PACIENTES CON TUMOR UROTELIAL DE VEJIGA TRATADOS CON CISTECTOMÍA RADICAL.
- Author
-
del Pozo Jiménez,, Gema, Herranz Amo, Felipe, Díez Cordero, José María, Monzó Gardiner, Juan Ignacio, Lledó García, Enrique, Subirá Ríos, David, Carballido Rodríguez, Joaquín, and Hernández Fernández, Carlos
- Published
- 2019
19. Cáncer de próstata de alto riesgo y diseminado (Documento de consenso de recomendaciones)
- Author
-
Castro Díaz, David, Dr., Gelabert Mas, Antoni, Dr., Allepuz Llosa, Carlos, Dr., Carballido Rodríguez, Joaquín, Dr., Manuel Cozar Olmo, José, Dr., Gómez-Veiga, Francisco, Dr., Hernández Fernández, Carlos, Dr., Llorente Abarca, Carlos, Dr., Morote Robles, Juan, Dr., Rodríguez-Antolín, lfredo, Dr., Solsona Narbón, Eduardo, Dr., Tabernero Prieto, Ángel, Dr., Unda Urzaiz, Miguel, Dr., and Villavicencio Mavrich, Humberto, Dr.
- Published
- 2005
- Full Text
- View/download PDF
20. Desarrollo de un programa de trasplante renal con órganos procedentes de donación tras asistolia controlada, tipo III de Maastricht
- Author
-
Portolés-Pérez, José, Rubio-Muñoz, Juan J., Lafuente-Covarrubias, Omar, Sánchez-Sobrino, Beatriz, Carballido-Rodríguez, Joaquín, Rodríguez-Reina, Gabriel, Rengifo-Abadd, Diego, Medina-Carrizo, Amparo, Sanz-Moreno, Carmen, and Fernández-Fernández, José
- Subjects
Donante tipo III Maastricht ,Maastricht type III donor ,Expanded criteria donor ,Non Heart-beating donor ,Donante criterios expandidos ,Donante en asistolia - Abstract
Introducción: La disponibilidad de donantes es el factor limitante para el trasplante renal. El donante en asistolia (DAS) no controlado proporciona hasta un tercio de los órganos. El DAS controlado tras limitación de técnicas de soporte vital (LTSV) o tipo III de Maastricht constituye una alternativa aún por desarrollar de forma sistemática. Tipo de estudio: Descriptivo, serie de 10 casos realizados entre enero y abril 2012. Métodos: A lo largo de 6 meses se diseña el protocolo de extracción y manejo del trasplante e inmunosupresión entre los equipos implicados. Se evalúan los pacientes de acuerdo con los criterios consensuados por un equipo distinto al responsable de coordinación de trasplante. Se establece un tiempo máximo 120 min desde LTSV hasta fallecimiento y de 60 min de isquemia caliente. Se utilizan dos tipos de perfusión de injerto, uno in situ por abordaje directo en lecho quirúrgico y otro con canalización vascular antemortem. La pauta de inmunosupresión incluye inducción con timoglobulina, esteroides y micofenolato e introducción de tacrolimus al séptimo día. Se muestran datos como mediana y (rango). Resultados: Se incluyen los 10 primeros casos de trasplante renal con órganos procedentes de 5 DAS tipo III de Maastricht: 4 varones, edad media 57 años (45-66), con LTSV por encefalopatía anóxica (2), intoxicación (1), accidente cerebrovascular agudo (2) e insuficiencia respiratoria terminal (1). Los tiempos registrados fueron: isquemia caliente efectiva de 20 min (8-23) e isquemia fría de 7,5 horas (4-14,1). Los receptores tenían 58 años (32-71), con distintas etiologías (2 glomerulonefritis, 1 poliquistosis, 2 nefropatía tubulointersticial, 4 vasculares y 1 no filiada), llevaban en hemodiálisis 31,7 meses (11-84) y para 2 de ellos era su segundo trasplante. Ninguno era hiperinmunizado. Seis pacientes precisaron alguna sesión de diálisis y cuatro presentaron necrosis tubular aguda prolongada, durante un ingreso de 24,5 días (8-44 d). La creatinina (Cr) al mes del trasplante fue de 2,1 mg/dl (0,7-3,2) y la Cr nadir fue de 1,2 mg/dl (0,7-3,2 mg/dl). Un paciente no mejoró su Cr por debajo de 3,2 mg/dl aunque la biopsia no mostró toxicidad ni rechazo, y su pareja de trasplante alcanzó una Cr de 1,4 mg/dl. En toda la serie se constataron complicaciones quirúrgicas similares a las de nuestra serie histórica de donantes convencionales. Conclusiones: Con las limitaciones de un estudio preliminar, el uso de este tipo de injertos presenta una evolución favorable a corto plazo. La utilización de este tipo de donante puede ayudar a reducir el tiempo de espera para un trasplante. Introduction: The availability of organ donors is a limiting factor for kidney transplants. Donations from non-heart-beating donors (NHBD) can provide as many as one-third of all organs. Controlled patients awaiting cardiac arrest following limitation of life support techniques, or type III Maastricht donors, constitute an alternative that still has yet to be systematically developed. Study type: Descriptive series of 10 cases occurring between January and April 2012. Method: Over a period of 6 months, we designed a protocol for extracting and managing kidney transplants and providing immunosuppression therapy. Patients are evaluated in accordance with the criteria agreed by a different team responsible for transplant coordination. We established a maximum duration of time between limitation of life-sustaining therapy and death of 120 minutes and 60 minutes warm ischaemia. Two types of graft perfusion were used, one in situ through direct application to the surgical area, and another using ante mortem vascular canalisation. Immunosuppression therapy included induction with thymoglobulin, steroids, and mycophenolate, with introduction of tacrolimus on the seventh day. Data are expressed as median and (range). Results: We included the first 10 cases of kidney transplants with organs from 5 NHBD (type III Maastricht): 4 males, mean age of 57 years (45-66 years), with limitation of life-sustaining therapy due to anoxic encephalopathy (2), intoxication (1), acute stroke (2) and terminal respiratory failure (1). The following mean time intervals were recorded: effective warm ischaemia: 20 minutes (8-23 minutes) and cold ischaemia: 7.5 hours (4-14.1 hours). Recipients had a mean age of 58 years (32-71 years), with various aetiologies (2 cases of glomerulonephritis, 1 polycystic kidney disease, 2 tubulo-interstitial nephropathy, 4 vascular, and 1 unknown), with a mean 31.7 months on haemodialysis (11-84 months); the kidney was a second transplant in two cases. No patients were hyper-immunised. Six patients required a dialysis session at some point, and four had prolonged acute tubular necrosis, over a mean hospitalisation period of 24.5 days (8-44 days). Mean creatinine (Cr) one month after transplantation was 2.1mg/dl (0.7-3.2mg/dl), and mean nadir creatinine was 1.2mg/dl (0.7-3.2mg/dl). One patient did not improve upon Cr values
- Published
- 2012
21. Evolución natural del carcinoma embrionario
- Author
-
López-González, Ana, Egui Rojo, María Alejandra, Maximiano, Constanza, Martínez-Salamanca, Juan Ignacio, González Hernando, Concepción, Sánchez Yuste, Rosario, Bonilla, Félix, and Carballido Rodríguez, Joaquín Alberto
- Subjects
Carcinoma embrionario ,Embryonal carcinoma - Abstract
Objetivo: Presentamos el caso de un varón de 37 años con un carcinoma embrionario en una forma poco frecuente en su debut, y que representa la historia natural de la enfermedad sin recibir atención sanitaria así como la efectividad del tratamiento con quimioterapia. Métodos: Paciente de 37 años con antecedentes de retraso mental desde el nacimiento, acude a urgencias por presentar una masa escrotal ulcerada maloliente de meses de evolución. Tras biopsia es diagnosticado de carcinoma embrionario pT4; en el estudio de extensión se evidencian múltiples nódulos pulmonares compatibles con metástasis. Recibió un total de cinco ciclos de Bleomicina/Etoposido/Cisplatino con una respuesta total tras el tratamiento. Resultados: Los tumores testiculares representan el tumor maligno sólido más frecuente en varones entre 20 y 39 años. Comprenden el 1% de todas las neoplasias masculina, y son responsables del 0,1% de todas las muertes por cáncer. Algunos autores apuntan que la incidencia real del tumor testicular ha aumentado y se sitúa alrededor del 3 % y se estima en 450 nuevos casos al año en España. Conclusiones: Con respecto al pronóstico de los tumores no seminomatosos, se acepta que la tasa de curación de los pacientes de riesgo intermedio se sitúa alrededor del 70% con tratamiento convencional con cuatro ciclos de BEP. El caso que presentamos resulta muy llamativo puesto que en nuestro medio los tumores testiculares son diagnosticados en estadios iniciales, sin afectación cutánea extensa, ni simulando otros tipos de tumores epiteliales y muestra la historia natural de la enfermedad. Objective: We report a rare case of advanced testicular cancer that describes the natural progression of testicular cancer without medical treatment. This study also describes the effectiveness of chemotherapy, which was the approach used for treatment. Methods: 37 year old male with history of mental retardation, presented to the emergency room with an ulcer on his right scrotum that had been present for a few months. He was diagnosed of pT4 embryonal carcinoma by biopsy. CT scan showed multiple lung nodes. He was treated with five cycles of Bleomycin/Etoposide/Cisplatin with complete response after treatment. Results: Testicular tumors are the most frequent solid tumors in males between the ages of 20 and 39 years old. Testicular tumors represent 1% of all neoplasias diagnosed in males and 0.1% of all male deaths due to cancer. Several studies have reported the current real incidence rate of testicular tumors has increased to 3%, which accounts for the diagnosis of 450 new cases of testicular cancer a year in Spain. Conclusions: The cure rate for patients with intermediate risk non-seminoma is around 70% following a conventional treatment approach of four cycles of BEP. The present case is noteworthy because, in our experience, testicular tumors are diagnosed at an early stage without extensively affecting the skin or simulating another type of epithelial tumor. As a result, the present study describes the natural progression of testicular cancer.
- Published
- 2010
22. USO DE INJERTO DE MUCOSA ORAL EN EL TRATAMIENTO DE ESTENOSIS URETERALES EXTENSAS: REVISIÓN DE CONJUNTO.
- Author
-
del Pozo Jiménez, Gema, Castillón-Vela, Ignacio, and Carballido Rodríguez, Joaquín
- Published
- 2017
23. REIMPLANTE URETERAL LAPAROSCÓPICO CON FLAP DE BOARI.
- Author
-
Castillón-Vela, Ignacio, del Pozo Jiménez, Gema, Turo Antona, Jorge, Vázquez Alba, David, Sáenz Medina, Javier, and Carballido Rodríguez, Joaquín
- Published
- 2017
24. Neuronal and non-neuronal bradykinin receptors are involved in the contraction and/or relaxation to the pig bladder neck smooth muscle
- Author
-
Ribeiro, Ana Sofía Fernandes, Leite Fernandes, Vitor Samuel, Martínez Sainz, María Del Pilar, Martínez-Sáenz, Ana, Pazos Rodríguez, María Ruth, Orensanz Muñoz, Luis Miguel, Recio Visedo, María Paz, Bustamante Alarma, Salvador, Carballido Rodríguez, Joaquín, García Sacristán, Albino, Prieto Ocejo, Dolores, Hernández Rodríguez, Medardo Vicente, Ribeiro, Ana Sofía Fernandes, Leite Fernandes, Vitor Samuel, Martínez Sainz, María Del Pilar, Martínez-Sáenz, Ana, Pazos Rodríguez, María Ruth, Orensanz Muñoz, Luis Miguel, Recio Visedo, María Paz, Bustamante Alarma, Salvador, Carballido Rodríguez, Joaquín, García Sacristán, Albino, Prieto Ocejo, Dolores, and Hernández Rodríguez, Medardo Vicente
- Abstract
Aims: The current study investigates the role played by bradykinin (BK) receptors in the contractility to the pig bladder neck smooth muscle. Methods: Bladder neck strips were mounted in myographs for isometric force recordings and BK receptors expression was also determined by immunohistochemistry. Results: B2 receptor expression was observed in the muscular layer and urothelium whereas B1 expression was consistent detected in urothelium. A strong B2 immunoreactivity was also observed within nerve fibers among smooth muscle bundles. On urothelium-denuded preparations basal tone, BK induced concentration-dependent contractions which were reduced in urothelium-intact samples, by extracellular Ca(2+) removal and by blockade of B2 receptors and voltage-gated Ca(2+) (VOC) and non-VOC channels, and increased by cyclooxygenase (COX) inhibition. On phenylephrine-precontracted denuded strips, under non-adrenergic non-cholinergic (NANC) conditions, electrical field stimulation-elicited frequency-dependent relaxations which were reduced by B2 receptor blockade. In urothelium-intact samples, the B1 receptor agonist kallidin promoted concentration-dependent relaxations which were reduced by blockade of B1 receptors, COX, COX-1 and large-conductance Ca(2+) -activated K(+) (BKCa ) channels and abolished in urothelium-denuded samples and in K(+) -enriched physiological saline solution-precontracted strips. Conclusions: These results suggest that BK produces contraction of pig bladder neck via smooth muscle B2 receptors coupled to extracellular Ca(2+) entry via VOC and non-VOC channels with a minor role for intracellular Ca(2+) mobilization. Facilitatory neuronal B2 receptors modulating NANC inhibitory neurotransmission and urothelial B1 receptors producing relaxation via the COX-1 pathway and BKCa channel opening are also demonstrated., Ministerio de Ciencia e Innovación (España), Fundação para a Ciência e Tecnologia, Ministério da Educação e Ciência (Portugal), Depto. de Fisiología, Fac. de Farmacia, TRUE, pub
- Published
- 2013
25. Evolución natural del carcinoma embrionario
- Author
-
López-González, Ana, primary, Egui Rojo, María Alejandra, additional, Maximiano, Constanza, additional, Martínez-Salamanca, Juan Ignacio, additional, González Hernando, Concepción, additional, Sánchez Yuste, Rosario, additional, Bonilla, Félix, additional, and Carballido Rodríguez, Joaquín Alberto, additional
- Published
- 2010
- Full Text
- View/download PDF
26. Comentario editorial de: Papel actual de la terapia combinada en la STUI masculina
- Author
-
Carballido Rodríguez, Joaquín, primary
- Published
- 2010
- Full Text
- View/download PDF
27. Fundamentos del láser y su aplicación en urología
- Author
-
Vázquez Alba, David, primary and Carballido Rodríguez, Joaquín, additional
- Published
- 2008
- Full Text
- View/download PDF
28. MEDICINA PERSONALIZADA Y CANCER DE PROSTATA. LA REALIDAD DE UN CAMBIO.
- Author
-
Carballido Rodríguez, Joaquín A. and Martínez-Salamanca, Juan I.
- Published
- 2015
29. 534 CANCER-SPECIFIC SURVIVAL NOMOGRAM FOR RENAL TUMORS WITH VENOUS EXTENSION:INTERNATIONAL RENAL CELL-CARCINOMA-VENOUS THROMBUS CONSORTIUM
- Author
-
Martinez-Salamanca, Juan Ignacio, Capitanio, Umberto, Huang, William, Millan, Isabel, Bertini, Roberto, Bianco, Fernando, Carballido Rodriguez, Joaquin, Ciancio, Gaetano, Hernandez, Carlos, Herranz Amo, Felipe, Haferkamp, Axel, Hohenfellner, Markus, Hu, Brian, Koppie, Theresa, Martinez-Ballesteros, Claudio, Montorsi, Francesco, Palou, Joan, Pontes, Edson, Terrone, Carlo, Russo, Paul, Sorcini, Andrea, Volpe, Alexadro, and Libertino, John
- Published
- 2011
- Full Text
- View/download PDF
30. 532 PROGNOSTIC ACCURACY OF THE 2009 UICC/AJCC TNM STAGING SYSTEM FOR RENAL CELL CARCINOMA WITH VENOUS EXTENSION
- Author
-
Martinez-Salamanca, Juan Ignacio, Huang, William, Millan, Isabel, Bertini, Roberto, Bianco, Fernando, Carballido Rodriguez, Joaquin, Ciancio, Gaetano, Hernandez, Carlos, Herranz Amo, Felipe, Haferkamp, Axel, Hohenfellner, Markus, Hu, Brian, Koppie, Theresa, Martinez-Ballesteros, Claudio, Montorsi, Francesco, Palou, Joan, Pontes, Edson, Russo, Paul, Terrone, Carlo, Volpe, Alexadro, and Libertino, John
- Published
- 2011
- Full Text
- View/download PDF
31. Efficacy and Safety of the Hexanic Extract of Serenoa repens vs. Watchful Waiting in Men with Moderate to Severe LUTS-BPH: Results of a Paired Matched Clinical Study
- Author
-
Antonio Alcaraz, Mauro Gacci, Vincenzo Ficarra, José Medina-Polo, Andrea Salonia, Jesús Fernández-Gómez, Alexandru Ciudin, David Castro-Díaz, Alfredo Rodríguez-Antolín, Joaquín Carballido-Rodríguez, José Cózar-Olmo, Santiago Búcar-Terrades, Noemí Pérez-León, Francisco Brenes-Bermúdez, José Molero-García, Antonio Ledesma, Michael Herdman, José Manasanch, Javier Angulo, on Group, Alcaraz, Antonio, Gacci, Mauro, Ficarra, Vincenzo, Medina-Polo, José, Salonia, Andrea, Fernández-Gómez, Jesús M, Ciudin, Alexandru, Castro-Díaz, David, Rodríguez-Antolín, Alfredo, Carballido-Rodríguez, Joaquín, Cózar-Olmo, José M, Búcar-Terrades, Santiago, Pérez-León, Noemí, Brenes-Bermúdez, Francisco J, Molero-García, José M, Ledesma, Antonio Fernández-Pro, Herdman, Michael, Manasanch, José, Angulo, Javier C, and Group, On Behalf Of The Qualiprost Study
- Subjects
hexanic extract of Serenoa repens ,quality of life ,moderate-severe LUTS ,BPH ,adverse effects ,sexual function ,General Medicine ,tolerability ,watchful waiting - Abstract
We investigated changes in symptoms and quality of life (QoL) in men with moderate-to-severe lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH) receiving the hexanic extract of Serenoa repens (HESr) and compared results with a matched group on watchful waiting (WW). Data was from a real-world, open-label, prospective, multicenter study. This sub-group analysis included patients with moderate-to-severe symptoms receiving either the HESr 320 mg/daily for six months (HESr) or who remained untreated for LUTS/BPH (WW). Changes in urinary symptoms and QoL were measured by IPSS and BII questionnaires. Two statistical approaches (iterative matching and propensity score pairing) were used to maximize between-group comparability at baseline. Tolerability was assessed in the HESr group. After iterative matching, data for analysis was available for 783 patients (102 WW, 681 HESr). IPSS scores improved by a mean (SD) of 3.8 (4.4) points in the HESr group and by 2.2 (4.5) points in the WW group (p = 0.002). Changes in BII score were 1.8 (2.4) points and 1.0 (2.2) points, respectively (p < 0.001). Three patients (0.9%) treated with the HESr reported mild adverse effects. Moderate-severe LUTS/BPH patients treated for six months with the HESr showed greater improvements in symptoms and QoL than matched patients on WW, with a very low rate of adverse effects.
- Published
- 2022
- Full Text
- View/download PDF
32. Trasplante Renal tras Donación en Asistolia Controlada tipo III de Maastricht. Experiencia y resultados en el 'Hospital Universitario Puerta de Hierro' entre los años 2012-2018
- Author
-
Ramírez Rodríguez-Bermejo, Patricia, Carballido Rodríguez, Joaquín, and UAM. Departamento de Cirugía
- Subjects
Medicina ,Cirugía - Abstract
Tesis Doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Cirugía. Fecha de Lectura: 17-01-2022
- Published
- 2022
33. Tratamiento de la fase aguda de la enfermedad de La Peyrinie mediante extensor peneano y correlación mediante ultrasonido
- Author
-
Egui Rojo, María Alejandra, Martinez Salamanca, Juan Ignacio, Carballido Rodríguez, Joaquín, and UAM. Departamento de Cirugía
- Subjects
Medicina ,Pene - Enfermedades - Tesis doctorales - Abstract
Tesis doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina, Departamento de Cirugía. Fecha de lectura: 15-06-2015
- Published
- 2015
34. Modelo predictivo para la supervivencia y la mortalidad perioperatoria en pacientes con carcinoma renal y extensión venosa tumoral: estudio internacional multi-institucional
- Author
-
Martínez Salamanca, Juan Ignacio, Carballido Rodríguez, Joaquín A., and Universidad Autónoma de Madrid. Departamento de Cirugía
- Subjects
Riñones - Cáncer - Cirugía - Tesis doctorales - Abstract
Tesis doctoral inédita leída en la Universidad Autónoma de Madrid, Facultad de Medicina. La tesis fue realizada en el Departmento del Cirugía de la UAM y el Servicio de Urología del Hospital Universitario Puerta de Hierro-Majadahonda. Fecha de lectura: 17 de Junio de 2011
- Published
- 2011
35. [Benign prostatic hyperplasia management during COVID-19 pandemia.]
- Author
-
Medina-Polo J, Téigell Tobar J, Romero-Otero J, Carballido-Rodríguez J, Domínguez-Esteban M, Martínez-Berganza ML, Miñana-López B, Unda Urzaiz JM, and Rodríguez-Antolín A
- Subjects
- Betacoronavirus, COVID-19, Humans, Lower Urinary Tract Symptoms etiology, Male, Referral and Consultation, SARS-CoV-2, Spain, Coronavirus Infections epidemiology, Pandemics, Pneumonia, Viral epidemiology, Prostatic Hyperplasia diagnosis, Prostatic Hyperplasia therapy
- Abstract
Objectives: The pandemic caused by the new SARS / Cov-2 Coronavirus represents an unprecedented scenario in modern medicine that affects many aspects of daily healthcare. Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) has a high prevalence and is related to high consumption of health resources. For this reason, we performed a revision of the management of LUTS and HBP during and after COVID-19 pandemic., Material and Methods: A group of experts in benign prostatic hyperplasia from different regions of Spain were selected to design a strategy to reorganize the management of benign prostatic hyperplasia and lower urinary tract symptoms during the pandemic. A comprehensive review of the literature was undertaken and a set of recommendations are generated., Results: Recommendations for the management of LUTS-BPH during and after the SARS/CoV2 coronavirus pandemic outbreak consist of promoting telemedicine and developing joint protocols with Primary Care Attention .Clear diagnostic and treatment criteria and referral criteria must be established. Referral of patients for risk complications such as kidney failure, recurrent hematuria and obstructive uropathy are a priority. Surgeries due to BPH are generally potentially delayed until phases I and II of the pandemic, in which the percentage of hospitalized patients with COVID-19 does not exceed 25%, and it is necessary to determine COVID19 negativity. The surgical technique that associates the least complications and the shortest stay should be selected., Conclusions: The diagnosis and prescription of treatment for BPH during the COVID-19 pandemic should be based on telemedicine and joint protocols for primary care attention and urology. Elective surgical treatment can be delayed until we are in phases I or II, individualizing the surgical and anaesthetic technique of choice to minimize risks.
- Published
- 2020
36. [Partial orchiectomy in testicular tumor: Surgical technique and role of intraoperatory ecography.]
- Author
-
Del Pozo Jiménez G, Castillón Vela I, Turo Antona J, Gimeno Collado A, and Carballido Rodríguez J
- Subjects
- Humans, Male, Organ Sparing Treatments, Ultrasonography, Orchiectomy, Testicular Neoplasms diagnostic imaging, Testicular Neoplasms surgery
- Abstract
Objectives: Systematic review of the treatment of small testicular masses (STM) by testicular sparing surgery (TSS), including indications, surgical techniques and complications, as well as the correlation of the analysis of frozen sections (FSE) with the final tumor histology. As a secondary objective we report the initial experience of our center in TSS., Material and Methods: A systematic literature search of the Medline/PubMed database for studies published until June 30, 2019 with the following keywords: "testis sparing surgery", "conservative surgery", "partial orquiectomy" "testicular neoplasms", "testis tumour", "Sex cord tumor", "intraoperative ultrasonography", "enucleation", "excision" or "resection" without time limits, in English and Spanish, identifying 20 articles with a total of 204 TSS, being the series with the largest sample size of 28. In our service, 8 TSS were performed in 6 patients (two bilateral tumor) distributed between 2016-2019., Results: No randomized controlled trials comparing TSS with radical orchiectomy have been reported. The indications for TSS are controversial, especially for patients with normal contralateral testicles. Tumor size has been identified as an important predictor of malignant disease and although there is no approved cut-off point, STM ≤2 cm are the ones that can benefit most from TSS. The use of intraoperative ultrasound (IU) is essential for the location of STM, whether a macroscopic or microsurgical resection is being performed, helping to reduce the rate of complications of the procedure, described in < 6%. The FSE is key at the time of the TSS, discriminating between benign and malignant neoplasms, maintaining a good correlation with the final histology., Conclusions: TSS for STM allows greater preservation of healthy parenchyma, but should be performed only in selected cases and in experienced centers. The surgical technique is safe and viable, the use of the IU and the FSE of the lesion being essential to facilitate the surgical decision making.
- Published
- 2019
37. Cavoscopy in the surgical treatment of renal cell carcinoma with vena cava thrombus. Systematic review.
- Author
-
Marcos Marín D, Del Pozo Jiménez G, Castillón Vela I, and Carballido Rodríguez J
- Subjects
- Cystoscopes, Humans, Vena Cava, Inferior, Carcinoma, Renal Cell complications, Carcinoma, Renal Cell surgery, Cystoscopy, Kidney Neoplasms complications, Kidney Neoplasms surgery, Neoplastic Cells, Circulating, Nephrectomy methods, Thrombosis complications, Thrombosis surgery
- Abstract
Objective: To perform a literature review on the use of cavoscopy during surgery for renal cell carcinoma with vena cava thrombus (RCCVCT), according to the criteria of Evidence-Based Medicine., Material and Methods: We performed a Pubmed search for studies published with the following keywords: "renal tumor thrombus", "renal tumor cavoscopy" and "cystoscopy thrombus", without time limit and in English. With these criteria, 5 articles were identified with a total of 41 patients. All studies found are case series and expert opinions, so the degree of evidence in the use of cavoscopy in RCCVCT is low., Results: RCCVCT surgery is a complex technique, which can reach over 50% 5-year survival, when a complete oncological resection is achieved. One of the keys for surgical success is complete resection of tumor thrombus, having used different techniques for its verification. One of them is cavoscopy, which consists on the introduction of a flexible cystoscope through the cavotomy incision after thrombectomy, checking the lumen of the vena cava with saline serum irrigation. In two series of clinical cases, cavoscopy detected thrombus persistence in 22% and 43% of patients respectively, allowing resection. The entire resected thrombus showed malignancy in several cases., Conclusion: Cavoscopy is a technique that improves detection of tumor remnants after thrombectomy in comparison to indirect review methods. Although oncological impact of caval thrombus is controversial, the use of cavoscopy allows a more complete resection of the thrombus, and it may offer a possible increase in the recurrence-free survival of these patients.
- Published
- 2019
38. Virtual reality and intracorporeal navigation in urology.
- Author
-
Del Pozo Jiménez G, Rodríguez Monsalve M, Carballido Rodríguez J, and Castillón Vela I
- Subjects
- Humans, User-Computer Interface, Surgery, Computer-Assisted, Urologic Surgical Procedures methods, Urology trends, Virtual Reality
- Abstract
Objective: To provide an overview of the meaning and types of virtual reality (VR) system, its current applications in the field of urology and future implications., Synthesis of the Evidence: The concept of VR involves the generation of computer environments with which a user can interact directly. Urology technologies and surgical practices are constantly evolving and RV simulation has become an important complement in urologist training curricula, taking into account not only simulations in surgical techniques, but also in non-surgical techniques such as communication and decision making. VR approaches for image-guided surgery have demonstrated potential in the field of urology by supporting guidance for various disorders. An increasing number of pre and intraoperative imaging modalities have been used to create detailed surgical route maps. The tracing of these surgical roadmaps with the surgical vision of real life has been produced in different ways (electromagnetic, acoustic, optical ...), recommending the combination of several approaches to provide a superior result. One of the disadvantages of navigation systems is soft tissue deformations, requiring confirmatory images. Although early studies report that navigation surgeries provide results equal to or greater than conventional approaches, most of the work has been done in relatively small groups of patients, thus requiring studies with larger sample sizes., Conclusions: The development of VR offers urologists many opportunities, with surgical simulation being one of its most important applications today. Likewise, the first clinical studies have demonstrated the potential of augmented reality (2D and 3D models) to improve surgical accuracy, describing different navigation systems for different urological surgical interventions.
- Published
- 2019
39. [Prognostic factors of mortality in patients with urothelial bladder tumor treated with radical cistectomy.]
- Author
-
Del Pozo Jiménez G, Herranz Amo F, Díez Cordero JM, Monzó Gardiner JI, Lledó García E, Subirá Ríos D, Carballido Rodríguez J, and Hernández Fernández C
- Subjects
- Aged, Humans, Male, Neoplasm Staging, Prognosis, Retrospective Studies, Survival Rate, Treatment Outcome, Cystectomy, Urinary Bladder Neoplasms diagnosis, Urinary Bladder Neoplasms surgery
- Abstract
Introduction: Radical cystectomy (RC) with pelvic lymphadenectomy is the treatment of choice in patients with muscle invasive bladder cancer (MIBC)., Objective: To identify clinical and pathological variables that influence global mortality (GM) and cancer specific mortality (CSM) in patients with urothelial bladder tumor (UBT) treated with RC. METHODS: Retrospective analysis of 517 patients diagnosed with UBT and treated with RC between 1986 and 2009. Demographic, clinical, surgical and pathological variables, as well as complications and evolution after RC were collected. A comparative analysis was carried out with Chi square and ANOVA test. Survival analysis was performed with the Kaplan-Meier method and the long-rank test. Univariate and multivariate analysis were performed using Cox regression to identify independent predictors of GM and CSM. RESULTS: 91% of the patients were males with a median age of 66 years. The most frequent local pathological stage was pT3 (32.6%), with lymph node involvement in 23.8% of the patients. After a median follow-up of 34 months, 170 patients were alive and 311 had died from any cause (63.5%), being UBT the cause of death in 225 patients (45%). Rates of global survival and cancer specific survival at 5 and 10 years were 45%/34.3% and 52.5%/46.6% respectively. On the multivariate analysis age ( p = 0.004), ASA ( p = 0.000), the existence of hydronephrosis ( p = 0.01), pT ( p = 0.000) and pN ( p = 0.003) were identified as independent predictors of GM, as well as pT ( p = 0.000) and pN ( p = 0.002) for CSM. CONCLUSIONS: Age, anesthetic risk, presence of hydronephrosis, pT and pN stage were identified as independent predictors of GM, as well as pT and pN stage for CSM.
- Published
- 2019
40. [Buccal mucosa graft for the treatment of long ureteral stenosis: Bibliographic review.]
- Author
-
Del Pozo Jiménez G, Castillón-Vela I, and Carballido Rodríguez J
- Subjects
- Humans, Ureteral Obstruction pathology, Urologic Surgical Procedures methods, Mouth Mucosa transplantation, Ureteral Obstruction surgery
- Abstract
Objective: To perform a literature review on the use of buccal mucosa graft (BMG) in the treatment of extensive ureteral stenosis, according to the criteria of Evidence Based Medicine., Methods: Pubmed search of published studies with the following keywords: "ureteral stricture treatment", "buccal mucosa graft ureteral treatment" and "buccal mucosa graft ureteroplasty", without time limits, in English and Spanish; 12 articles were identified with a total of 48 cases (46 patients) of BMG use in ureteral repair., Results: The main etiologies of ureteral stenosis, where BMG has been applied, have been iatrogenic and inflammatory strictures. This graft has been used complicamainly in proximal or middle ureter stenosis, as a patch according to onlay technique or as a tubularized graft. Early and late complications of the procedure have been reported in 16.7% and 10.4%, respectively, with a restenosis rate of 6.25%. A 91.6% success rate was observed with this technique, with an average follow-up time of 22 (3-85) months., Conclusions: The findings of the present review do not justify the universal use of BMG in all ureteral strictures, particularly in the absence of long-term followup, but still provide evidence that BMG can be effectively used in extensive ureteral strictures.
- Published
- 2017
41. [Laparoscopic Boari Flap ureteral reimplantation.]
- Author
-
Castilló-Vela I, Del Pozo Jiménez G, Turo Antona J, Vázquez Alba D, Sáenz Medina J, and Carballido Rodríguez J
- Subjects
- Adult, Aged, Humans, Male, Middle Aged, Cystostomy methods, Laparoscopy, Replantation methods, Surgical Flaps, Ureter surgery, Ureterostomy methods
- Abstract
Objectives: To report our initial experience with laparoscopic Boari flap ureteral reimplantation and to review the main technical elements in ureteral reconstructive surgery., Methods: In a 10-year period we performed 23 laparoscopic ureteral reimplantations. Three cases required a Boari flap. Two patients presented ureteral stenosis above the iliac vessels and the third one a urothelial tumor of the pelvic ureter., Results: Two cases were completed laparoscopically; the third one was electively converted to open surgery to avoid prolonged OR time. Mean operative time was 276 minutes (270-290 min). There were no intraoperative complications. Mean hospital stay was 6.6 days. One patient presented postoperative UTI (Clavien 2). One patient developed with history of sever arteriopathy and aortorenal by pass developed ureteral stenosis proximal to the ureteral reimplantation eight months after the operation., Conclusions: Laparoscopic Boari flap ureteral reimplantation is an affective technique for ureteral reconstruction, safe and reproducible, reserved for cases of ureteral pathology in which the distance to bridge between the bladder and the ureteral stump is long.
- Published
- 2017
42. [Personalized medicine and prostate cancer. The reality of change].
- Author
-
Carballido Rodríguez JA and Martínez-Salamanca JI
- Subjects
- Humans, Male, Precision Medicine, Prostatic Neoplasms diagnosis, Prostatic Neoplasms therapy
- Abstract
Prostate cancer (PCa) is a public health problem in western male populations on the basis of it's high incidence and prevalence. Nowadays we come to changes in the diagnostic technologies that deserve special attention and that once applied allow to show the way towards a personalized view of PCa being able to join this modern current trend of the oncologic pathology. In spite of the recognized heterogeneity of the disease; clinical, pathological and genetic variants in genes and the limitations of the PSA as a biomarker to determine the biological aggressiveness of PCa, the certain thing is that the therapeutic final decision is adopted on the basis of a distant information to the wished customization and it moves excessive uncertainty for patients.In this respect the search based on the identification of alterations on the genomic sequence and it's influence in the molecular characterization of the PCa is a constant in the investigation since nowadays. Actually, the progressive adjournment to the clinic of information tumour information that comes from the diagnostic tests related genetic material or their biochemical products, though still in initial phase, already allows to predict relevant changes in molecular characterization of the prostate cancer, in the eventual availability of predictive biomarkers from susceptibility to suffer the disease and of the personalized stratification of risk across the incorporation of newly and interesting molecular and immunohistochemistry biomarkers. Likewise the advances in the perspectives opened with the diagnosis, and the relevance in the decisions of biopsy indications that stem from it are based on the utilization, with the corresponding merger of images, of the multiparametric magnetic resonance (mpMRI) and the new prostate ecographic transrectal images with it's natural evolution towards focal treatments represent, in spite of the recognized complex interpretation of the images, another significant transformation towards the individualization and ideally customization of the clinical decisions opposite to a certain patient with PCa. Events all of them, even more, if they are considered to be combined turn out to be very promising and it's integration brings us over to personalized medicine in PCa since already it happens in others, though still small, neoplastic diseases. All this aspects are summarized and discussed in the present article in the light of the recent communicated information and the reflection and personal experience of the authors. Finally chasing how to improve the clinical managing and the treatment for patients with PCa.
- Published
- 2015
43. Avanafil for the treatment of erectile dysfunction. An updated review.
- Author
-
Egui-Rojo MA, Moncada-Iribarren I, Carballido-Rodríguez J, and Martínez-Salamanca JI
- Subjects
- Adult, Humans, Male, Treatment Outcome, Erectile Dysfunction drug therapy, Phosphodiesterase 5 Inhibitors therapeutic use, Pyrimidines therapeutic use
- Abstract
Objectives: Avanafil is a highly selective phosfosdiesterase 5 inhibitor (PDE5 inhibitor), with rapid onset of action, approved by the Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of erectile dysfunction (ED). It had been recently commercialized in Spain. This article presents a detailed review of the available literature, where the safety, tolerability and efficacy of avanafil were evaluated., Methods: A systematic literature search using the Medline database was performed. The search included the terms Avanafil and erectile dysfunction. The pivotal studies of clinical development of the drug, and also those randomized, double-blind, placebo-controlled, well-designed studies were analyzed. We included those studies published in English up to January 2014. Likewise, studies of the pharmacokinetics and pharmacodynamics of the drug were also included., Results: The avanafil pivotal studies, conducted in general population of patients with ED, patients with Diabetes mellitus type I and II and patients with ED secondary to nerve sparing radical prostatectomy were analyzed. In all these studies, avanafil demonstrated a statistically significant improvement in erectile function (IIEF), and all the coprimary outcomes (SEP2 and SEP3) compared to placebo. Also, a good tolerance profile and few side effects compared to placebo were evident., Conclusions: Avanafil is a selective PDE5 inhibitors, that is rapidly absorbed and that has a short time to peak response. It found to be effective in randomized, double-blind, placebo-controlled trials conducted in men with erectile dysfunction, including in patients with diabetes mellitus and after radical prostatectomy. It was generally well tolerated across trials, with very few patients withdrawing because of adverse effects. Similarly, avanafil had a significantly lower rate of hemodynamic side effects compared with sildenafil.
- Published
- 2014
44. Development of a program for kidney transplants using organs donated from donors awaiting cardiac arrest (type III Maastricht).
- Author
-
Portolés-Pérez J, Rubio-Muñoz JJ, Lafuente-Covarrubias O, Sánchez-Sobrino B, Carballido-Rodríguez J, Rodríguez-Reina G, Rengifo-Abadd D, Medina-Carrizo A, Sanz-Moreno C, and Fernández-Fernández J
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Program Development, Heart Arrest classification, Kidney Transplantation, Tissue Donors, Tissue and Organ Procurement methods
- Abstract
Introduction: The availability of organ donors is a limiting factor for kidney transplants. Donations from non-heart-beating donors (NHBD) can provide as many as one-third of all organs. Controlled patients awaiting cardiac arrest following limitation of life support techniques, or type III Maastricht donors, constitute an alternative that still has yet to be systematically developed., Study Type: Descriptive series of 10 cases occurring between January and April 2012., Method: Over a period of 6 months, we designed a protocol for extracting and managing kidney transplants and providing immunosuppression therapy. Patients are evaluated in accordance with the criteria agreed by a different team responsible for transplant coordination. We established a maximum duration of time between limitation of life-sustaining therapy and death of 120 minutes and 60 minutes warm ischaemia. Two types of graft perfusion were used, one in situ through direct application to the surgical area, and another using ante mortem vascular canalisation. Immunosuppression therapy included induction with thymoglobulin, steroids, and mycophenolate, with introduction of tacrolimus on the seventh day. Data are expressed as median and (range)., Results: We included the first 10 cases of kidney transplants with organs from 5 NHBD (type III Maastricht): 4 males, mean age of 57 years (45-66 years), with limitation of life-sustaining therapy due to anoxic encephalopathy (2), intoxication (1), acute stroke (2) and terminal respiratory failure (1). The following mean time intervals were recorded: effective warm ischaemia: 20 minutes (8-23 minutes) and cold ischaemia: 7.5 hours (4-14.1 hours). Recipients had a mean age of 58 years (32-71 years), with various aetiologies (2 cases of glomerulonephritis, 1 polycystic kidney disease, 2 tubulo-interstitial nephropathy, 4 vascular, and 1 unknown), with a mean 31.7 months on haemodialysis (11-84 months); the kidney was a second transplant in two cases. No patients were hyper-immunised. Six patients required a dialysis session at some point, and four had prolonged acute tubular necrosis, over a mean hospitalisation period of 24.5 days (8-44 days). Mean creatinine (Cr) one month after transplantation was 2.1mg/dl (0.7-3.2mg/dl), and mean nadir creatinine was 1.2mg/dl (0.7-3.2mg/dl). One patient did not improve upon Cr values <3.2mg/dl, despite the absence of evidence of toxicity or rejection in a renal biopsy, and the transplant pair reached a Cr of 1.4mg/dl. Throughout the series, similar surgical complications were recorded to those observed in conventional donor situations., Conclusions: Despite the limitations of this preliminary study, the use of this type of transplant produces favourable short-term evolution. Expanded use of this type of donor could reduce the waiting-list time for a kidney transplant.
- Published
- 2012
- Full Text
- View/download PDF
45. [Epidemiological fundamentals of clinically localized prostate cancer].
- Author
-
Martínez-Salamanca JI, Ballesteros CM, and Carballido Rodríguez J
- Subjects
- Adenocarcinoma blood, Adenocarcinoma diagnosis, Adenocarcinoma pathology, Adenocarcinoma therapy, Adult, Age Distribution, Aged, Aged, 80 and over, Androgens, Biomarkers, Tumor blood, Diet, Diseases in Twins epidemiology, Europe epidemiology, Genetic Predisposition to Disease, Global Health, Humans, Incidence, Insulin-Like Growth Factor I physiology, Male, Middle Aged, Neoplasms, Hormone-Dependent epidemiology, Prostate-Specific Antigen blood, Prostatic Neoplasms blood, Prostatic Neoplasms diagnosis, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy, Risk Factors, Adenocarcinoma epidemiology, Prostatic Neoplasms epidemiology
- Abstract
Prostate cancer is the sixth most common cancer in the world (in the number of new cases), the third most common cancer in men, and the most common cancer in men in Europe, North America, and some parts of Africa. Different geographical regions have varying incidence and mortality. The risk of prostate cancer is increased by African-American ethnicity, increasing age, positive family history, and other factors such as diet. Nonetheless, the causes of prostate cancer are not well understood compared with other common cancers like lung and breast cancer. The introduction of prostate-specific antigen (PSA) screening made an enormous impact on the incidence of prostate cancer, which increased in the early 1990s and is currently down to pre-PSA screening levels. Screening has caused a change in pattern of disease to an earlier stage but not lower grade. Yet we know little about what causes this disease, in the past 10 years interest in and funding for prostate cancer research have increased and several promising risk modifiers have been identified-eg, genetic predisposition, insulin growth factor (IGF) concentrations, and lycopene consumption.
- Published
- 2011
46. [Localized prostate cancer. Quo vadis?].
- Author
-
Carballido Rodríguez J
- Subjects
- Adenocarcinoma pathology, Forecasting, Humans, Male, Prostatic Neoplasms pathology, Adenocarcinoma therapy, Prostatic Neoplasms therapy
- Published
- 2011
47. [Prostate biopsy: Diagnostic responsibility and recent changes].
- Author
-
Martínez-Ballesteros C, Martínez-Salamanca JI, and Carballido Rodríguez JA
- Subjects
- Adenocarcinoma diagnosis, Adenocarcinoma diagnostic imaging, Anesthesia, Local, Forecasting, Humans, Male, Models, Theoretical, Neoplasm Grading, Prostatic Intraepithelial Neoplasia diagnosis, Prostatic Intraepithelial Neoplasia diagnostic imaging, Prostatic Intraepithelial Neoplasia pathology, Prostatic Neoplasms diagnosis, Prostatic Neoplasms diagnostic imaging, Risk Factors, Ultrasonography, Interventional, Urology education, Adenocarcinoma pathology, Biopsy, Needle methods, Biopsy, Needle trends, Prostatic Neoplasms pathology
- Abstract
In this bibliographic review we reexamine the different features in relation to indication, performance and interpretation of prostatic biopsy (PB). The main objective is to place methodological features involving PB in the current scientific scenario, establishing the correlation between the most relevant and analyzing the historic evolution this procedure has followed, particularly over the last two decades. Prostate biopsy has evolved to be a regular element in urologists` daily practice and its learning process has been simplified to the point it can be approached with adequacy during the first years of residency in Urology. This privileged position PB enjoys in daily practice and the performance obtained from it would have not been a reality without optimization of transrectal ultrasound or local anesthesia techniques, yet reviled in some forums, the real responsible of such success. The consensus reached in the various scientific associations, the clinical guidelines of which are widely consulted worldwide, is the best to support the current state of the art, being the starting point for the addition of new improvements to PB.
- Published
- 2011
48. Natural progression of embryonal carcinoma.
- Author
-
López-González A, Egui Rojo MA, Maximiano C, Martínez-Salamanca JI, González Hernando C, Sánchez Yuste R, Bonilla F, and Carballido Rodríguez JA
- Subjects
- Adult, Carcinoma, Embryonal drug therapy, Disease Progression, Humans, Male, Testicular Neoplasms drug therapy, Carcinoma, Embryonal pathology, Testicular Neoplasms pathology
- Abstract
Objective: We report a rare case of advanced testicular cancer that describes the natural progression of testicular cancer without medical treatment. This study also describes the effectiveness of chemotherapy, which was the approach used for treatment., Methods: 37 year old male with history of mental retardation, presented to the emergency room with an ulcer on his right scrotum that had been present for a few months. He was diagnosed of pT4 embryonal carcinoma by biopsy. CT scan showed multiple lung nodes. He was treated with five cycles of Bleomycin/Etoposide/Cisplatin with complete response after treatment., Results: Testicular tumors are the most frequent solid tumors in males between the ages of 20 and 39 years old. Testicular tumors represent 1% of all neoplasias diagnosed in males and 0.1% of all male deaths due to cancer. Several studies have reported the current real incidence rate of testicular tumors has increased to 3%, which accounts for the diagnosis of 450 new cases of testicular cancer a year in Spain., Conclusions: The cure rate for patients with intermediate risk non-seminoma is around 70% following a conventional treatment approach of four cycles of BEP. The present case is noteworthy because, in our experience, testicular tumors are diagnosed at an early stage without extensively affecting the skin or simulating another type of epithelial tumor. As a result, the present study describes the natural progression of testicular cancer.
- Published
- 2010
49. [Current role for combination therapy in male LUTS. Editorial comment].
- Author
-
Carballido Rodríguez J
- Subjects
- 5-alpha Reductase Inhibitors therapeutic use, Adrenergic alpha-Antagonists therapeutic use, Drug Therapy, Combination, Humans, Male, Prostatic Hyperplasia complications, Prostatic Hyperplasia drug therapy, Prostatism etiology, Prostatism drug therapy
- Published
- 2010
- Full Text
- View/download PDF
50. [The basics of laser and its application in urology].
- Author
-
Vázquez Alba D and Carballido Rodríguez J
- Subjects
- Humans, Laser Therapy methods, Urologic Diseases surgery, Urologic Surgical Procedures methods, Urology methods
- Abstract
A laser, light amplification by stimulated emission of radiation, is a device able to transform other energies into electromagnetic radiation with emission of light beams of different wavelengths. They amplify the light and produce coherent light beams, the frequency of which varies from infrared to X ray. Stimulated emission, the process laser is based on, was described by A. Einstein in 1917, but it was not until the decade of the '60s when the first laser process was observed in a ruby crystal. Depending on the environment they use, lasers may be named as solid-state, gas, semiconductors or liquid. The possibility of uses for laser is almost unlimited, becoming a very valuable tool in biomedical sciences thanks to the various effects they produce when interacting with tissues (photovaporization, photodisruption, photocoagulation or photostimulation). For this reason, today, the use of lasers in the field of urology offers a wide range of possibilities, going from surgery for the treatment of obstruction, such as the fragmentation of a urinary stone or resection/ablation of prostatic tissue, to reconstructive surgery, such as tissue welding in vasovasostomy or urethral stenosis repair.
- Published
- 2008
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.